Pepinemab for Treatment of Younger Patients with Recurrent, Relapsed, or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of pepinemab (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after progression on prior treatment, or did not respond to prior treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
About the Trial
This is a single-arm, open label study. Patients receive pepinemab in the absence of disease progression or unacceptable toxicity. Primary objectives include safety and antitumor activity with respect to disease control rate at 4 months in pediatric patients with recurrent or refractory patients.
Active, not recruiting
View Trial on ClinicalTrials.gov
National Trial Reference Number
Actual Study Start Date
January 12, 2018
Estimated Primary Completion Date
December 31, 2020
Estimated Study Completion Date
December 31, 2021
Children’s Oncology Group
National Cancer Institute (NCI)
Only a qualified healthcare professional can determine your eligibility.
However, this information may be useful in starting a conversation with your doctor.